Company Overview - Yimufeng Biotech is a leading global innovative cell therapy company, with its core product IMC002 being a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate, currently in pivotal Phase III clinical trials for solid tumors [2] - The company also has a first-in-class anti-EpCAM CAR-T cell therapy candidate (IMC001) in Phase I/IIa clinical trials, targeting various epithelial-derived tumors, and a proprietary manufacturing process for cost-effective CAR-T production [3] - Yimufeng Biotech aims to leverage the large patient population for solid tumors in China and globally, creating significant market potential [2] Financial Information - For the fiscal year 2024, the company reported other income and revenue of approximately 3.36 million RMB, 2.137 million RMB for the nine months ended September 30, 2024, and 2.877 million RMB for the nine months ended September 30, 2025 [4] - Research and development expenses for the fiscal year 2024 were recorded at 54.44 million RMB, 38.574 million RMB for the nine months ended September 30, 2024, and 48.694 million RMB for the nine months ended September 30, 2025 [5] Industry Overview - CAR-T therapy is expanding significantly from hematologic malignancies to solid tumors and autoimmune diseases, presenting substantial growth opportunities [8] - The treatment shows promising efficacy against blood cancers, and researchers are developing innovative strategies to address challenges in solid tumor treatment [8] - The CAR-T field is evolving through traditional technology improvements and the development of new platforms, with next-generation CAR designs enhancing targeting precision and safety [8]

Company Overview - Shenzhen Yimufeng Biotechnology Co., Ltd. is a leading global innovative cell therapy company, with its core product IMC002 being a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate, currently in Phase III clinical trials for treating solid tumors [4] - The company also has a first-in-class anti-EpCAM CAR-T cell therapy candidate IMC001 in Phase I/IIa clinical trials, targeting various epithelial-derived tumors [5] - Yimufeng has developed a proprietary manufacturing process for CAR-T therapies that is expected to offer significant cost advantages, addressing key industry pain points [4] Financial Information - The company reported other income and revenue of approximately RMB 3.36 million for the fiscal year 2024, RMB 2.137 million for the nine months ending September 30, 2024, and RMB 2.877 million for the nine months ending September 30, 2025 [6][8] - Research and development expenses were RMB 54.44 million for the fiscal year 2024, RMB 38.574 million for the nine months ending September 30, 2024, and RMB 48.694 million for the nine months ending September 30, 2025 [7][8] Industry Overview - CAR-T therapy is expanding from hematologic malignancies to solid tumors and autoimmune diseases, presenting significant growth opportunities due to the large patient population [9] - The global incidence of gastric cancer is projected to increase from 893.6 thousand cases in 2019 to 1,017.4 thousand cases in 2024, with a compound annual growth rate (CAGR) of 2.6% [14] - In China, the annual incidence of gastric cancer is expected to rise from 329.7 thousand cases in 2019 to 376.1 thousand cases in 2024, with a CAGR of 2.7% [17]

Group 1 - The core viewpoint of the article is that Shenzhen Yimufeng Biotechnology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as its sole sponsor [1] - Yimufeng Biotechnology is described as a global leader in innovative cell therapy, focusing on its core product IMC002, which is a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate [1] - The IMC002 therapy is currently in a critical clinical phase (Phase III clinical trial) and is noted to be the second in clinical progress globally among solid tumor CAR-T therapy candidates [1]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Shenzhen Immunofoco Biotechnology Co., Ltd. 深圳易慕峰生物科技股份有限公司 (A joint stock company incorporated in the People's Rep ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Shenzhen Immunofoco Biotechnology Co., Ltd. 深圳易慕峰生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向深圳易慕峰生物科技股份有限公司（「本公司」）、本公司的獨家保 薦人、保薦人兼整體協調人、顧問及包銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記 前，本公司不會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀 請，有意投資者務請僅依據於香港公司註冊處處長註冊的本公司招股章程作出投資決定，招股 章程 ...